FR3114739B1 - Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique - Google Patents

Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique Download PDF

Info

Publication number
FR3114739B1
FR3114739B1 FR2010186A FR2010186A FR3114739B1 FR 3114739 B1 FR3114739 B1 FR 3114739B1 FR 2010186 A FR2010186 A FR 2010186A FR 2010186 A FR2010186 A FR 2010186A FR 3114739 B1 FR3114739 B1 FR 3114739B1
Authority
FR
France
Prior art keywords
peptoids
prevention
treatment
new
chronic pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2010186A
Other languages
English (en)
French (fr)
Other versions
FR3114739A1 (fr
Inventor
Jérôme Busserolles
Emmanuel Bourinet
Claude Taillefumier
Olivier Roy
Lionel Nauton
Youssef Aissouni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Université Clermont Auvergne
Sigma Clermont
Original Assignee
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Université Clermont Auvergne
Sigma Clermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2010186A priority Critical patent/FR3114739B1/fr
Application filed by Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, University of Montpellier, Université Clermont Auvergne, Sigma Clermont filed Critical Centre National de la Recherche Scientifique
Priority to PCT/FR2021/051694 priority patent/WO2022074313A1/fr
Priority to CA3194875A priority patent/CA3194875A1/fr
Priority to JP2023521558A priority patent/JP7853288B2/ja
Priority to CN202180068718.2A priority patent/CN116744957A/zh
Priority to ES21798748T priority patent/ES3005857T3/es
Priority to EP21798748.6A priority patent/EP4225295B1/fr
Priority to US18/248,240 priority patent/US20230374067A1/en
Publication of FR3114739A1 publication Critical patent/FR3114739A1/fr
Application granted granted Critical
Publication of FR3114739B1 publication Critical patent/FR3114739B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR2010186A 2020-10-06 2020-10-06 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique Active FR3114739B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2010186A FR3114739B1 (fr) 2020-10-06 2020-10-06 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
CA3194875A CA3194875A1 (fr) 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
JP2023521558A JP7853288B2 (ja) 2020-10-06 2021-09-30 新規ペプトイド及び慢性疼痛の予防又は治療におけるそれらの使用
CN202180068718.2A CN116744957A (zh) 2020-10-06 2021-09-30 新类肽及其在预防或治疗慢性疼痛中的用途
PCT/FR2021/051694 WO2022074313A1 (fr) 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
ES21798748T ES3005857T3 (en) 2020-10-06 2021-09-30 Novel peptoids and use thereof for preventing or treating chronic pain
EP21798748.6A EP4225295B1 (fr) 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
US18/248,240 US20230374067A1 (en) 2020-10-06 2021-09-30 Novel peptoids and use thereof for preventing or treating chronic pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2010186A FR3114739B1 (fr) 2020-10-06 2020-10-06 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
FR2010186 2020-10-06

Publications (2)

Publication Number Publication Date
FR3114739A1 FR3114739A1 (fr) 2022-04-08
FR3114739B1 true FR3114739B1 (fr) 2022-08-26

Family

ID=74553909

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2010186A Active FR3114739B1 (fr) 2020-10-06 2020-10-06 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique

Country Status (8)

Country Link
US (1) US20230374067A1 (enExample)
EP (1) EP4225295B1 (enExample)
JP (1) JP7853288B2 (enExample)
CN (1) CN116744957A (enExample)
CA (1) CA3194875A1 (enExample)
ES (1) ES3005857T3 (enExample)
FR (1) FR3114739B1 (enExample)
WO (1) WO2022074313A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
KR20080038408A (ko) * 2005-08-18 2008-05-06 쉬바르츠파르마에이지 근육통 치료를 위한 펩티드 화합물의 신규한 용도
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
JP7120927B2 (ja) * 2016-06-07 2022-08-17 江蘇恒瑞医薬股▲ふん▼有限公司 フェニルプロパンアミド誘導体ならびにそれらの製造方法および医薬用途
US11753432B2 (en) * 2017-01-27 2023-09-12 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain

Also Published As

Publication number Publication date
US20230374067A1 (en) 2023-11-23
EP4225295B1 (fr) 2024-11-13
JP7853288B2 (ja) 2026-04-28
EP4225295C0 (fr) 2024-11-13
CA3194875A1 (fr) 2022-04-14
CN116744957A (zh) 2023-09-12
EP4225295A1 (fr) 2023-08-16
ES3005857T3 (en) 2025-03-17
WO2022074313A1 (fr) 2022-04-14
JP2023544842A (ja) 2023-10-25
FR3114739A1 (fr) 2022-04-08

Similar Documents

Publication Publication Date Title
Goto et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
EP3993868A4 (en) DEVICES, SYSTEMS AND METHODS FOR NON-INVASIVE THERAPY OF CHRONIC PAIN
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MA39767B1 (fr) Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec
MA49673A (fr) Combinaison comprenant du palbociclib etde l'acide 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphényl]-8,9-dihydro-7h-benzo [7]annulène-2-carboxylique et son utilisation pour le traitement du cancer
MA39311A1 (fr) Préparation anti-pigmentation pour bain de bouche a base de chlorhexidine pour la prevention ou le traitement cosmetique ou therapeutique de la plaque dentaire
MA50790A (fr) Posologie de vidofludimus à utiliser dans la prévention ou le traitement de maladies inflammatoires chroniques et/ou auto-immunes
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
EP4232032A4 (en) Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders
MA57599B1 (fr) Semaglutide pour le traitement de la démence d'alzheimer
MA44935A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires
FR2930447B1 (fr) Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
EA202092305A1 (ru) Соединения в качестве модуляторов сигнализации tlr2
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3813870C0 (en) CCR5 INHIBITOR FOR USE IN THE TREATMENT OF CANCER
FR2930552B1 (fr) N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
MA55274A (fr) Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
EP4119159A4 (en) MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
MA58093B1 (fr) Nouveaux analogues d'insuline et leurs utilisations
CR20230406A (es) Métodos para detectar especies tau de csf con etapa y progresión de la enfermedad de alzheimer, y uso de estos
Hao et al. Acupuncture ameliorates Alzheimer’s-like cognitive impairment and pathological changes via regulating the intestinal fungal community in APP/PS1 mice
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220408

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6